Duration of pertussis immunity after DTaP immunization: A meta-analysis

Pediatrics

Volumn 135, Issue 2, 2015, Pages 331-343

  McGirr, Ashleigh ^a   Fisman, David N ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; ACELLULAR VACCINE; BACTERIUM ANTIBODY; VACCINE;

ARTICLE; BACTERIAL IMMUNITY; CHILD HEALTH CARE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNIZATION; INCIDENCE; META ANALYSIS; OBSERVATIONAL STUDY; PERTUSSIS; STUDY DESIGN; VACCINE FAILURE; BLOOD; BORDETELLA PERTUSSIS; CHILD; FOLLOW UP; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INFANT; PRESCHOOL CHILD;

ANTIBODIES, BACTERIAL; BORDETELLA PERTUSSIS; CHILD; CHILD, PRESCHOOL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FOLLOW-UP STUDIES; HUMANS; IMMUNE TOLERANCE; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INFANT; VACCINE POTENCY; VACCINES, ACELLULAR; WHOOPING COUGH;

EID: 84922657818     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2014-1729     Document Type: Article

References (71)

1. Public Health Agency of Canada. Canadian immunization guide. In: Public Works and Government Services. 7th ed. Ottawa, Canada: Public Health Agency of Canada; 2006
2. McWha L, MacArthur A, Badiani T, Schouten H, Tam T, King A. Measuring up: results from the National Immunization Coverage Survey, 2002. Can Commun Dis Rep. 2004;30(5):37-50
3. Galanis E, King AS, Varughese P, Halperin SA; IMPACT Investigators. Changing epidemiology and emerging risk groups for pertussis. CMAJ. 2006;174(4):451-452
4. Ntezayabo B, De Serres G, Duval B. Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr Infect Dis J. 2003;22(1):22-27
5. Fisman DN, Tang P, Hauck T, et al. Pertussis resurgence in Toronto, Canada: a population-based study including test-incidence feedback modeling. BMC Public Health. 2011;11:S58-S61
6. Wood N, McIntyre P. Pertussis: review of epidemiology, diagnosis, management and prevention. Paediatr Respir Rev. 2008;9(3):201-211; quiz 211-202
7. Raguckas SE, VandenBussche HL, Jacobs C, Klepser ME. Pertussis resurgence: diagnosis, treatment, prevention, and beyond. Pharmacotherapy. 2007;27(1):41-52
8. Lavine JS, Bjørnstad ON, de Blasio BF, Storsaeter J. Short-lived immunity against pertussis, age-specific routes of transmission, and the utility of a teenage booster vaccine. Vaccine. 2012;30(3):544-551
9. Tartof SY, Lewis M, Kenyon C, et al. Waning immunity to pertussis following 5 doses of DTaP. Pediatrics. 2013;131(4). Available at: www.pediatrics.org/cgi/content/full/131/4/e1047
10. Klein NP, Bartlett J, Rowhani-Rahbar A, Fireman B, Baxter R. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med. 2012;367(11):1012-1019
11. De Serres G. An Advisory Committee Statement (ASC). National Advisory Committee on Immunization (NACI). Statement on adult/adolescent formulation of combined acellular pertussis, tetanus, and diphtheria vaccine. Can Commun Dis Rep. 2000;26:1-8
12. Cody CL, Baraff LJ, Cherry JD, Marcy SM, Manclark CR. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics. 1981;68(5):650-660
13. Public Health Agency of Canada. An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Statement on the Booster for 4-6 Year-Olds for Protection Against Pertussis. Ottawa, Canada: Public Health Agency of Canada; 2014
14. Ontario Ministry of Health and Long Term Care. Publically Funded Immunization Schedules for Ontario - August 2011. Toronto, Canada: Government of Ontario; 2011
15. European Centre for Disease Prevention and Control. Recommended immunisations for pertussis. 2013. Available from: http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx. Accessed December 14, 2013
16. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J. 2005;24(5 suppl):S58-S61
17. Google. Google Translate; 2013
18. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377-384
19. Sanderson S, Tatt ID, Higgins JP. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol. 2007;36(3):666-676
20. Greco D, Salmaso S, Mastrantonio P, et al; Progetto Pertosse Working Group. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med. 1996;334(6):341-348
21. Giuliano M, Mastrantonio P, Giammanco A, Piscitelli A, Salmaso S, Wassilak SG. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one wholecell vaccine against pertussis. J Pediatr. 1998;132(6):983-988
22. Sänger R, Behre U, Krause KH, et al. Booster vaccination and 1-year follow-up of 4-8-year-old children with a reduced-antigen-content dTpa-IPV vaccine. Eur J Pediatr. 2007;166(12):1229-1236
23. Rothman KJ. Epidemiology: An Introduction. New York, NY: Oxford University Press; 2012
24. Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36(3):1-48
25. R: A Language and Environment for Statistical Computing [computer program]. Vienna, Austria: R Foundation for Statistical Computing; 2006.
26. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634
27. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188
28. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558
29. Zhang L, Prietsch SO, Axelsson I, Halperin SA. Acellular vaccines for preventing whooping cough in children. Cochrane Database Syst Rev. 2014;9:CD001478
30. Advisory Committee on Immunization Practices. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46(RR-7):1-25
31. Briand V, Bonmarin I, Lévy-Bruhl D. Study of the risk factors for severe childhood pertussis based on hospital surveillance data. Vaccine. 2007;25(41):7224-7232
32. Bisgard KM, Rhodes P, Connelly BL, et al; Centers for Disease Control and Prevention. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001. Pediatrics. 2005;116(2). Available at: www.pediatrics.org/cgi/content/full/116/2/e285
33. Campbell H, Amirthalingam G, Andrews N, et al. Accelerating control of pertussis in England and Wales. Emerg Infect Dis. 2012;18(1):38-47
34. Carlsson RM, Trollfors B. Control of pertussis - lessons learnt from a 10-year surveillance programme in Sweden. Vaccine. 2009;27(42):5709-5718
35. Choe YJ, Park YJ, Jung C, Bae GR, Lee DH. National pertussis surveillance in South Korea 1955-2011: epidemiological and clinical trends. Int J Infect Dis. 2012;16(12):e850-e854
36. Edelman K, He Q, Makinen J, et al. Immunity to pertussis 5 years after booster immunization during adolescence. Clin Infect Dis. 2007;44(10):1271-1277
37. Edelman KJ, He Q, Makinen JP, et al. Pertussis-specifi c cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine. Clin Infect Dis. 2004;39(2):179-185
38. Esposito S, Agliardi T, Giammanco A, et al. Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine in comparison with that after natural infection. Infect Immun. 2001;69(7):4516-4520
39. Esposito S, Faldella G, Giammanco A, et al. Long-term pertussis-specific immune responses to a combined diphtheria, tetanus, tricomponent acellular pertussis and hepatitis B vaccine in pre-term infants. Vaccine. 2002;20(23-24):2928-2932
40. Ey JL, Duncan B, Barton LL, Buckett G. The influence of preschool pertussis immunization on an epidemic of pertussis. Pediatr Infect Dis J. 1991;10(8):576-578
41. Gustafsson L, Hessel L, Storsaeter J, Olin P. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics. 2006;118(3):978-984
42. Gzyl A, Augustynowicz E, Rabczenko D, Gniadek G, Slusarczyk J. Pertussis in Poland. Int J Epidemiol. 2004;33(2):358-365
43. Hallander HO, Gustafsson L, Ljungman M, Storsaeter J. Pertussis antitoxin decay after vaccination with DTPa: response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine. 2005;23(46-47):5359-5364
44. Lacombe K, Yam A, Simondon K, Pinchinat S, Simondon F. Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children. Vaccine. 2004;23(5):623-628
45. Le T, Cherry JD, Chang SJ, et al; APERT Study. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT study. J Infect Dis. 2004;190(3):535-544
46. Lin YC, Yao SM, Yan JJ, et al. Epidemiological shift in the prevalence of pertussis in Taiwan: implications for pertussis vaccination. J Med Microbiol. 2007;56(pt 4):533-537
47. Misegades LK, Winter K, Harriman K, et al. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA. 2012;308(20):2126-2132
48. Moerman L, Leventhal A, Slater PE, Anis E, Yishai R, Marva E. The re-emergence of pertussis in Israel. Isr Med Assoc J. 2006;8(5):308-311
49. Mossong J, Putz L, Shkedy Z, Schneider F. Seroepidemiology of diphtheria and pertussis in Luxembourg in 2000. Epidemiol Infect. 2006;134(3):573-578
50. Okada K, Ueda K, Morokuma K, Fukushige J, Miyazaki C. Comparison of antibody titers in eleven- to twelve-year old Japanese school children six years after administration of acellular and whole cell pertussis vaccines combined with diphtheria-tetanus toxoids. Pediatr Infect Dis J. 1998;17(12):1167-1169
51. Olin P, Gustafsson L, Barreto L, et al. Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. Vaccine. 2003;21(17-18):2015-2021
52. Ozkal A, Sensoy G, Acuner C, Belet N, Güney AK. Seroprevalence of Bordetella pertussis immunoglobulin G antibodies among children in Samsun, Turkey. Turk J Pediatr. 2012;54(1):15-19
53. Paulke-Korinek M, Fischmeister G, Grac A, et al. Persistence of antibodies in 4-8 year old Austrian children after vaccination with hexavalent DTaP-HBV-IPV/Hib and MMR vaccines. Vaccine. 2011;29(32):5130-5136
54. Ramsay ME, Corbel MJ, Redhead K, Ashworth LA, Begg NT. Persistence of antibody after accelerated immunisation with diphtheria/tetanus/pertussis vaccine. BMJ. 1991;302(6791):1489-1491
55. Salmaso S, Mastrantonio P, Tozzi AE, et al; Stage III Working Group. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics. 2001;108(5). Available at: www.pediatrics.org/cgi/content/full/108/5/E81
56. Tindberg Y, Blennow M, Granström M. A ten year follow-up after immunization with a two component acellular pertussis vaccine. Pediatr Infect Dis J. 1999;18(4):361-365
57. Tomovici A, Barreto L, Zickler P, et al. Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine. Vaccine. 2012;30(16):2647-2653
58. White JM, Fairley CK, Owen D, Matthews RC, Miller E. The effect of an accelerated immunisation schedule on pertussis in England and Wales. Commun Dis Rep CDR Rev. 1996;6(6):R86-R91
59. Witt MA, Katz PH, Witt DJ. Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak. Clin Infect Dis. 2012;54(12):1730-1735
60. Zepp F, Habermehl P, Knuf M, Mannhardt-Laakman W, Howe B, Friedland LR. Immunogenicity of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine. Vaccine. 2007;25(29):5248-5252
61. Zinke M, Disselhoff J, Gartner B, Jacquet JM; DTP a-HBV-IPV-110 and -111 Study Groups. Immunological persistence in 4-6 and 7-9 year olds previously vaccinated in infancy with hexavalent DTPa-HBV-IPV/Hib. Hum Vaccin. 2010;6(2):189-193
62. Public Health Agency of Canada. Notifiable disease on-line.2014. Available at: http://dsol-smed.phac-aspc.gc.ca/dsol-smed/ndis/charts.php?c=pl. Accessed September 15, 2014
63. National Center for Immunization and Respiratory Disease. 2013 Provisional Pertussis Surveillance Report. Atlanta, GA: US Centers for Disease Control and Prevention; 2014
64. Broder KR, Cortese MM, Iskander JK, et al; Advisory Committee on Immunization Practices (ACIP). Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55(RR-3):1-34
65. Healy CM, Rench MA, Baker CJ. Importance of timing of maternal combined tetanus, diphtheria, and acellular pertussis (Tdap) immunization and protection of young infants. Clin Infect Dis. 2013;56(4):539-544
66. Lee GM, Riffelmann M, Wirsing von Konig CH. Cost-effectiveness of adult pertussis vaccination in Germany. Vaccine. 2008;26(29-30):3673-3679
67. Cherry JD. The present and future control of pertussis. Clin Infect Dis. 2010;51(6):663-667
68. Chiappini E, Stival A, Galli L, de Martino M. Pertussis re-emergence in the post-vaccination era. BMC Infect Dis. 2013;13: 151-163
69. Knuf M, Zepp F, Meyer C, et al. Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population. Vaccine. 2006;24(12):2043-2048
70. Zinke M, Kappes R, Kindler K, et al. Immune memory to hepatitis B virus in 4-9-year old children vaccinated in infancy with four doses of hexavalent DTPa-HBV-IPV/Hib vaccine. Hum Vaccin. 2009;5(9):592-598
71. Simondon F, Preziosi MP, Yam A, et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine. 1997;15(15):1606-1612